Celebrex, Mobic Not Worth Extra Expense, Journal Analysis Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
Payors and consumers overspent nearly $6 bil. over three years by choosing celecoxib and meloxicam over traditional, less-expensive therapies, according to Journal of Managed Care Pharmacy.